A Phase 2B Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs VX 150 (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 15 Feb 2019 Status changed from recruiting to completed.
- 05 Feb 2019 According to a Vertex Pharmaceuticals media release, data from this study is expected in the first half of 2019
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.